As shown in the five studies presented below, the JETi™ thrombectomy device demonstrated positive clinical outcomes in a variety of thrombosis cases.
Pin, R. on behalf of the JETi Registry Investigators, Primary analysis of the novel JETi™ mechanical thrombectomy system for the treatment of arterial thrombosis. LINC, Leipzig, Germany 2024 May 28-31.
The JETi Registry (JETi Peripheral Thrombectomy Registry NCT04370691) is an all-comers, prospective, single-arm, multicenter, post-market study designed to collect real-world data on the JETi™ Hydrodynamic Thrombectomy System.
Razavi et al., JVIR. 2021.
Prospective study investigating single-session treatment of iliocaval and iliofemoral venous thrombosis while evaluating potential for treatment on an outpatient basis.
Dandu et al., VAM. 2022.
Retrospective review of 27 patients treated with JETi™ for acute and subacute lower limb ischemia.
Khalsa et al., JVIR. 2020.
Retrospective review of 30 patients treated with JETi for acute lower extremity venous thrombosis.
Cournoyer-Rodrigue et al., JVIR. 2019.
Retrospective evaluation of 18 consecutive acute venous thrombosis patients at a new JETi user facility.
MAT-2116430 v3.0
The JETi™ Hydrodynamic Thrombectomy System is intended to remove/aspirate fluid and break-up soft emboli and thrombus from the peripheral vasculature and to sub-selectively infuse/deliver diagnostics or therapeutics with or without vessel occlusion.
The JETi™ Hydrodynamic Thrombectomy System is contraindicated for use in:
Fluid | Maximum Recommended Fluid Delivery Flow Rate |
---|---|
Saline | 4.0 mL/s |
60% Ionic Contrast Media | 1.8 mL/s |
Potential adverse events include, but are not limited to:
JETi™ is a trademark of Walk Vascular. Walk Vascular is a subsidiary of the Abbott Group of Companies.
Manufactured by Walk Vascular LLC 17171 Daimler Street, Irvine CA, 92614 USA
MAT-2116195 v3.0
Stay Connected